Population pharmacokinetics of flucytosine: Comparison and validation of three models using STS, NPEM, and NONMEM

Therapeutic Drug Monitoring

Volumn 22, Issue 6, 2000, Pages 676-687

  Vermes, Andras ^a   Mathôt, Ron A A ^b   Van Der Sijs, I Heleen ^a   Dankert, Jacob ^a   Guchelaar, Henk Jan ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Slotervaartziekenhuis ^*  (Netherlands)

Author keywords

Flucytosine; NONMEM; NPEM; Population pharmacokinetics; STS

Indexed keywords

FLUCYTOSINE;

ACCURACY; ADULT; AGED; ARTICLE; COMPARTMENT MODEL; DISTRIBUTION VOLUME; DRUG ELIMINATION; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; PRIORITY JOURNAL; RELIABILITY; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; BODY FLUID COMPARTMENTS; COMPUTER SIMULATION; DRUG MONITORING; FEMALE; FLUCYTOSINE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; NONLINEAR DYNAMICS; REPRODUCIBILITY OF RESULTS; STATISTICS, NONPARAMETRIC;

EID: 0033647263     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200012000-00006     Document Type: Article

References (49)

1. The synthesis of 5-fluoropyrimidines
2. Studies on fluorinated pyrimidines. II. Effects on transplanted tumors
3. Chemotherapeutic activity of 5-fluorocytosine
4. Treatment of Candida species and Cryoptococcus meningitis with 5-fluorocytosine. A new antifungal agent
5. 5-Fluorocytosine in human cryptococcosis
6. Evolving role of flucytosine in immunocom-promised patients: New insights into safety, pharmacokinetics, and antifungal therapy
7. Clinical use of systemic antifungal agents
8. Antifungal agents used in systemic mycoses. Activity and therapeutic use
9. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis
10. Flucytosine
11. Mode of action of 5-fluorocytosine
12. Mode of action of 5-fluorocytosine
13. Antimicrobial agents. Antifungal agents
14. Flucytosine
15. Mechanisms of action of 5-fluorocytosine
16. Flucytosine kinetics in subjects with normal and impaired renal function
17. Pharmacological studies with 5-fluorocytosine
18. Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function
19. Flucytosine: Correlation between toxicity and pharmacokinetic parameters
20. Clinical pharmacokinetics of systemic antifungal drugs
21. Treatment of disseminated candidiasis with 5-fluorocytosine
22. Bone marrow toxicity associated with 5-fluorocytosine therapy
23. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis
24. Therapy of cryptococcosis with a combination of flucytosine and amphotericin B
25. In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata
26. Adverse drug reactions to systemic antifungals. Prevention and management
27. MW/PHARM, an integrated software package for drug dosage regimen and therapeutic drug monitoring
28. Liquid-chromatographic determination of 5-fluorocytosine
29. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations
30. A new look at the statistical model identification
31. The NONMEM system
32. Some suggestions for measuring predictive performance
33. Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method
34. Population pharmacokinetics of gentamicin. Use of the nonparametric expectation maximisation (NPEM) algorithm
35. Comparison of population pharmacokinetic models for gentamicin in spinal cord-injured and able-bodied patients
36. Individualizing drug dosage regimens: Roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control
37. Population pharmacokinetics of racemic warfarin in adult patients
38. One-point feedback control method for phenytoin dosage adjustment
39. Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: Application to pefloxacin in intensive care unit patients
40. The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers
41. The pharmacokinetics of propofol in children using three different data analysis approaches
42. Population pharmacokinetics/pharmacodynamics modeling: Parametric and nonparametric methods
43. Preliminary results of three methods of population pharmacokinetic analysis (NONMEM, NPML, NPEM) of amikacin in geriatric and general medicine patients
44. Software for population pharmacokinetics and pharmacodynamics
45. Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime